trisalicylate choline Report issue

Small molecule Experimental
AACT DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now
Choline magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Choline magnesium trisalicylate inhibits inflammation-related prostaglandin synthesis. Choline magnesium trisalicylate is used to relieve the pain, tenderness, inflammation (swelling), and stiffness caused by arthritis and painful shoulder. It is also used to relieve pain and lower fever. Salicylate intoxication, known as salicylism, may occur with large doses or extended therapy. Common symptoms of salicylism include headache, dizziness, tinnitus, hearing impairment, confusion, drowsiness, sweating, vomiting, diarrhea, and hyperventilation. A more severe degree of salicylate intoxication can lead to CNS disturbances, alteration in electrolyte balance, respiratory and metabolic acidosis, hyperthermia, and dehydration.   NCATS

Chemistry

  • SMILES: [Mg++].C[N+](C)(C)CCO.OC1=C(C=CC=C1)C([O-])=O.OC2=C(C=CC=C2)C([O-])=O.OC3=C(C=CC=C3)C([O-])=O
  • InChIKey: FQCQGOZEWWPOKI-UHFFFAOYSA-K
  • Mol. Mass: 539.8142
  • ALogP: Missing data
  • ChEMBL Molecules: Missing data
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

((1,2-ethanediylbis(carbamodithioato))(2-))manganese, mixt. with ((1,2-ethanediylbis(carbamodithioato))(2-))zinc &2(or 4)-isooctyl-4,6(or 2,6)-dinitrophenyl 2-buten oate | choline magnesium trisalicylate | tegunor | tricosal | trilisate | trisalicylate choline

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Leukemia (Phase 2)

Leukemia, Monocytic, Acute (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Acute (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue